KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Issued (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Issued for 18 consecutive years, with $13.2 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Issued fell 73.35% year-over-year to $13.2 million; the TTM value through Mar 2026 reached $213.8 million, down 34.5%, while the annual FY2025 figure was $250.0 million, 17.47% down from the prior year.
  • Shares Issued hit $13.2 million in Q1 2026 for Alnylam Pharmaceuticals, down from $41.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $153.0 million in Q3 2022 and bottomed at $13.2 million in Q1 2026.
  • Average Shares Issued over 5 years is $57.2 million, with a median of $42.4 million recorded in 2023.
  • Year-over-year, Shares Issued crashed 83.79% in 2023 and then surged 335.54% in 2024.
  • Alnylam Pharmaceuticals' Shares Issued stood at $56.7 million in 2022, then crashed by 45.53% to $30.9 million in 2023, then rose by 17.43% to $36.3 million in 2024, then grew by 14.95% to $41.7 million in 2025, then tumbled by 68.45% to $13.2 million in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $13.2 million, $41.7 million, and $77.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.